were stimulated to study the immunological reactivity of patients with Crohn's disease because of histological features which it shares with sarcoidosis. Both diseases are characterized by the presence of granulomata, with multinucleate giant cells and epithelioid cells surrounded by aggregates of mononuclear cells. Caseation is usually absent in both conditions. In Crohn's disease the granulomata are less numerous, less well formed, and less cellular than in sarcoidosis: they are usually confined to the gut and its draining lymph nodes, though they have occasionally been reported in the liver.
Boeck (1916) noted that many patients with sarcoidosis had a depression of tuberculin sensitivity. Friou (1952) and Citron (1957) showed that this was part of a generalized depression of delayed hypersensitivity, and that the response to oidiomycin, tricophytin, and mumps antigen was also impaired.
The tuberculin response in patients with Crohn's disease was first studied by Blackburn et al (1939) . Out of 17 patients, 12 (70%) failed to show delayed hypersensitivity to 0.01 mg of tuberculin. Phear (1958) found that 24 patients (69 %) out of 35 failed to respond to 10 TU of old tuberculin, and Williams (1965) reported that 32 (64%) out of 50 cases failed to respond to 10 TU. None of these workers studied control groups; however, in 1939 it would have been most unusual to find a population of healthy young adults of whom 70% were tuberculin negative. Fletcher and Hinton (1967) controls to oidiomycin, tricophytin, and mumps antigen, and found no significant difference between the two groups. They concluded that 'patients with regional ileitis react normally to antigens which demonstrate delayed hypersensitivity'. There are, however, disadvantages in using natural antigens to test for delayed hypersensitivity. A variable number of normal subjects will fail to respond because they have never previously encountered the antigen, and it may be necessary to compare large groups of patients and controls in order to show a significant difference. With the fall in tuberculin positivity in the adult population, Mantoux testing now presents similar difficulties.
It is possible, however, to study directly the ability of an individual to develop delayed hypersensitivity to a new antigen, dinitrochlorobenzene (DNCB). This is a hapten which, after combining with proteins in the cells of the dermis, acts as a potent antigen and will produce delayed hypersensitivity in 90% of normal subjects (Kligman and Epstein, 1959) . Aisenberg (1962) used DNCB to study the ability of patients with Hodgkin's disease to develop delayed hypersensitivity, and discussed in detail the criteria for distinguishing a positive (specific) hypersensitivity reaction from non-specific chemical irritation. Dinitrochlorobenzene has also been used extensively in the United States in normal subjects (Kligman and Epstein, 1959; Aisenberg, 1962; Gross, 1965) and in children with immunological deficiencies (Young, Austen, and Moser, 1964) as well as in patients with cancer (Gross, 1965) and with leprosy (Waldorf, Sheagren, Trautman, and Block, 1966) . There have been no reports of any dangers or complications. Testing with DNCB in patients with sarcoidosis, Jones (1967) showed impairment of the response in patients in whom the disease was active. The object of the present work was to assess the ability of patients with Development of delayed hypersensitivity to dinitrochlorobenzene in patients with Crohn's disease 53
Crohn's disease to develop delayed hypersensitivity to DNCB, and to relate this to their response to tuberculin and to their clinical condition.
PATIENTS
Twenty-six patients with Crohn's disease were studied. The diagnosis was based on histological examination of surgical specimens or on typical clinical and radiological findings. Details of the patients are given in Table I . Only one (C.T.) was receiving corticosteroid treatment when the skin tests were performed.
METHODS
For the Mantoux test 100 units of tuberculin were injected intradermally. The injection site was inspected at 72 hours, and the test was regarded as positive if there was an area of induration of 4 mm or more in diameter.
DNCB SENSITIZATION The method used was described by Jones (1967) and was essentially the same as that used by Aisenberg (1962) . A circular area of skin 2 cm in diameter on the volar surface of the forearm was surrounded by a barrier cream, and 0-1 ml of a 10 % solution of 2,4-dinitro-1-chlorobenzene (DNCB) in acetone was dropped slowly on to the skin. The solution was evaporated in a stream of air, and the area was covered for 24 hours. The presence of DNCB sensitization was tested three weeks later by applying 0.1 ml of a 0-1 % solution of DNCB in acetone to the opposite forearm in the same way. The test was read at 72 hours, and if necessary, after one week. In normal individuals the lesion became raised, with vesiculation and underlying induration. This was regarded as a positive reaction (Fig. 1 ).
In some patients there was erythema without vesiculation or induration, and this was regarded as a negative response. of giant cells in the deeper layers (Fig. 2) Neither had been tuberculin-tested after BCG. Enell s with Crohn's (1955) found that when a large group of schoolOut of 26, 11 children were retested with 100 TU at yearly interit 15 failed to vals after being given BCG, between 0.5 and 150%
)f the DNCB-became negative each year. At the end of 10 years, iled to respond one would expect between 5 and 15 % of a group of ive group, only patients to have reverted to a negative Mantoux te.
reaction. We therefore feel that it is at least possible ,ults of DNCB that two of our patients reverted from being features of the Mantoux positive to being Mantoux negative after ith the activity developing Crohn's disease. We conclude that there from the ESR is evidence that some patients with Crohn's disease have a generalized depression of delayed hypersensitivity.
This type of immunological abnormality is common to several other diseases. Aisenberg (1962) x Positive Total showed that most patients with active Hodgkin's 5 15 disease failed to respond to DNCB, and that this 7 11 correlated well with their tuberculin anergy.
with active sarcoidosis also failed to respond to DNCB, and Waldorf et al (1966) demonstrated an impaired response to DNCB in a proportion of patients with lepromatous leprosy. Among the patients with sarcoidosis, and those with leprosy, a few individuals were found who retained a positive tuberculin test, although negative to DNCB; this happened in four of our patients with Crohn's disease. This appears at first sight anomalous, since DNCB is a powerful antigen and the ability to develop sensitivity to DNCB is regarded as definitive evidence of the 'state of the delayed hypersensitivity mechanism in the individual' (Aisenberg, 1962) . However, there is extensive evidence from animal work (see, for example, de Weck and Frey, 1966) that it is easier to prevent the development of delayed hypersensitivity to a new antigen than it is to abolish an already existing response. Moreover, tuberculin and DNCB are testing different aspects of the immune response since DNCB is testing the induction and expression of hypersensitivity to a new antigen, while the Mantoux reaction tests the ability to express an already established immunity (Jones, 1967) . The significance of the impairment of delayed hypersensitivity in Crohn's disease is at present obscure. We believe that it is now a fact which must be taken into account in any reasonable hypothesis of the aetiology of the disease.
SUMMARY
The ability to develop delayed hypersensitivity to tuberculin and to dinitrochlorobenzene (DNCB), a potent chemical antigen, has been studied in 26 patients with Crohn's disease. Fifteen out of the 26 patients failed to develop delayed hypersensitivity to dinitrochlorobenzene. Twenty out of 20 control subjects developed delayed hypersensitivity to DNCB in the normal way.
Of the 15 DNCB-negative patients, 10 (67 %) also failed to develop delayed hypersensitivity to 100 TU of old tuberculin. Of the 11 DNCB-positive patients, only four (36 %) were tuberculin-negative. There was no correlation between the response to DNCB and the extent or activity of the Crohn's disease. 
